Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...

Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Notching another deal in its efforts to extend the global reach of toripalimab, Junshi Biosciences Co. Ltd. granted Dr. Reddy’s Laboratories Ltd. rights to develop and commercialize the PD-1 inhibitor ...

Please provide your email address to receive an email when new articles are posted on . Adding toripalimab to gemcitabine-cisplatin chemotherapy significantly improved PFS and overall response rates ...

Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...

SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180 ...

The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener The latest update ...

A new immunotherapy, toripalimab, has the potential to change practice in the treatment of nasopharyngeal carcinoma (NPC), say experts. The drug is a monoclonal antibody that blocks programmed cell ...